Fycompa (Perampanel) Patent Expiration, LOE Window & CMS Spending

Fycompa (Perampanel) by Catalyst: FDA Orange Book core substance LOE 2026-07-01, 4 AB generics, $176.0M 2024 CMS Part D & Medicaid spend, and 14 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCatalyst
FDA Application & PathwayN202834 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2026-07-01
Last Listed Patent or Exclusivity Date2026-07-01
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$176.0M
2024 Medicare Part D Spend$75.7M
2024 Medicaid Spend$100.3M
Reported Wholesale Price Change (CA SB 17)14 WAC filings (max 16.5% 2-yr change)